Caribou Bioscience, Inc (CRBU)
1.66
+0.06 (3.75%)
Upcoming Events
Latest Headlines
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
June 12, 2026 8:10 AM - StreetInsider
Form 8-K Caribou Biosciences, For: Jun 11
June 11, 2026 8:03 AM - SEC Filing
Caribou reports long-term data for vispa-cel in lymphoma patients
June 11, 2026 8:02 AM - StreetInsider
Caribou Biosciences reports durable responses for CB-011 therapy
June 11, 2026 8:01 AM - StreetInsider
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
June 11, 2026 8:01 AM - Globe NewsWire
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
June 11, 2026 8:00 AM - Globe NewsWire
Form DEFA14A Caribou Biosciences,
June 5, 2026 4:01 PM - SEC Filing
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
May 27, 2026 4:05 PM - Globe NewsWire
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
May 13, 2026 4:05 PM - Globe NewsWire
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
May 12, 2026 9:30 AM - Globe NewsWire
Caribou Biosciences Inc. (CRBU) PT Raised to $11 at H.C. Wainwright
May 11, 2026 6:59 AM - StreetInsider
Caribou Biosciences, Inc. (CRBU) Tops Q1 EPS by 7c
May 7, 2026 6:02 PM - StreetInsider
Form 10-Q Caribou Biosciences, For: Mar 31
May 7, 2026 4:17 PM - SEC Filing
Form 8-K Caribou Biosciences, For: May 07
May 7, 2026 4:13 PM - SEC Filing
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026 4:06 PM - Globe NewsWire
Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference
May 5, 2026 4:05 PM - Globe NewsWire
Form DEFR14A Caribou Biosciences,
May 1, 2026 4:03 PM - SEC Filing
Form ARS Caribou Biosciences, For: Dec 31
April 24, 2026 4:04 PM - SEC Filing
Form DEFA14A Caribou Biosciences,
April 24, 2026 4:02 PM - SEC Filing
Form DEF 14A Caribou Biosciences, For: Dec 31
April 24, 2026 4:02 PM - SEC Filing
Form PRE 14A Caribou Biosciences, For: Dec 31
April 10, 2026 4:02 PM - SEC Filing
Caribou Biosciences receives FDA RMAT designation for CB-011 therapy
March 31, 2026 8:05 AM - StreetInsider
Form 8-K Caribou Biosciences, For: Mar 31
March 31, 2026 8:03 AM - SEC Filing
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
March 31, 2026 8:00 AM - Globe NewsWire
Full Article List
